Sector News

Sanofi plowing as much as $2B into biologics production

June 14, 2017
Life sciences

Following the recent approval of two new biologics, Dupixent and Kevzara, and a pipeline stuffed full of large-molecule drugs, Sanofi will invest as much as €2 billion on its biologics manufacturing network over the next several years.

The disclosure came today during a media event, Reuters reports, and was confirmed by a spokesman for the French drugmaker. Philippe Luscan, executive VP of global industrial affairs, said at the event that the company will plow €600 million ($673 million) a year on its biologics production over the next two to three years.

“The investments will reinforce our three major hubs in the U.S., Germany and France,” where Sanofi is doing production of biologics like monoclonal antibodies (mAbs), spokesman Nicolas Kressmann said in a telephone interview. The investments will be for capacity expansion and hiring at different sites in those hubs, he said.

“It’s part of the €1 billion that we invest every year in our global industrial network,” Kressmann explained, with the rest of the money going into small molecule production. The investments are in line with what the drugmaker has been doing for several years, he added.

That comes on top of the €270 million ($286.3 million) Sanofi and Swiss contractor Lonza earlier this year said they will jointly spend to build a plant at Lonza’s site in Visp, Switzerland, which they will share for the production of biologics. That facility, which is expected to employ 200, is slated to be complete at the end of 2019 and operational in 2020.

With about 72% of its R&D projects made up of to biologic drugs, many made from cells, the French drugmaker, like its peers, has shifted its spending to concentrate on production of these more complex drugs. It has chosen to work with contractors for some of its needs. Two years ago, it transferred production on monoclonal antibodies (mAbs) it was working on with its sometimes-partner Regeneron to a Boehringer Ingelheim plant in Germany.

Sanofi’s own production work with mAbs has not always been stellar. In October, when it and partner Regeneron had expected to receive approval of rheumatoid arthritis drug sarilumab, the two instead were issued a complete response letter tied to problems at a plant in France that was doing the fill-finish work on the drug, as well as for dupilumab, which at the time was pending FDA approval as a treatment for a severe form of eczema.

After resolving issues to the FDA’s satisfaction, the two won approval in March for dupilumab, which they branded Dupixent. Late last month, they received the delayed approval of sarilumab, rolled out as Kevzara, for which they are looking at peak sales of as much as $5 billion a year.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.